Search | Clinical Trials Finder

Conditions: Hyperglycemia
Interventions: Metformin, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions: Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis); Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Atrial Fibrillation
Interventions: Metformin; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Rimonabant, Placebo (for Rimonabant), Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions: Metformin XR, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more

Conditions: Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions: Metformin, Omega-3 fatty acids; Drug
Lead sponsor: Katherine D. Crew; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: NAFLD
Interventions: Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo; Drug
Lead sponsor: NuSirt Biopharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Placebo, Lifestyle Intervention; Drug · Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years to 39 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels; Other
Lead sponsor: Foundation for Atlanta Veterans Education and Research, Inc.; Other
Eligibility: 40 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Stroke
Interventions: Telmisartan, Metformin, Cilostazol; Drug
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Healthy Participants
Interventions: Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Depression, Fatigue, Sleep Disorders
Interventions: Metformin, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 252
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 185 more

Conditions: Type 2 Diabetes Mellitus
Interventions: AR-C165395XX, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cancer
Interventions: Metformin; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more

Conditions: Asthma, Asthma Chronic, Overweight and Obesity
Interventions: Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tablets; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Other Conditions That May Be A Focus of Clinical Attention
Interventions: Metformin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Francsico, California

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia
Interventions: Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Healthy
Interventions: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Search by objective public record fields.

Metformin Use in Patients Undergoing Total Joint Replacement Surgery

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

Metformin as an Upstream Therapy in Atrial Fibrillation

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects

Feasibility Study of Metformin Therapy in ADPKD

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions